Skip to main content
. 2017 Sep 21;8(50):87658–87666. doi: 10.18632/oncotarget.21142

Figure 3. SF-PreCon attenuates the secondary injury after tSCI through the inhibition of COX-2 expression.

Figure 3

(A) Real-time PCR and western blotting assay for COX-2 mRNA and protein levels in tSCI rats with or without 1.0 MAC SF-PreCon. Data are mean ± SEM; * P < 0.05 versus the Sham group; # P < 0.05 versus the Vehicle group; unpaired two-tailed Student's t-test. n = 5 per group. (B) Representative slides of TUNEL staining of the spinal cord sections with or without NS-398 treatment. Magnification = ×100. (C) Percentage of TUNEL-positive cell in B were calculated. Data are mean ± SEM; ** P < 0.01 versus the Sham group; # P < 0.05 versus the Vehicle group; unpaired two-tailed Student's t-test. n = 5 per group. (D-G) ELISA of cytokines IL-1α (D), IL-1β (E), IL-6 (F), and TNF-α (G) in tSCI rats with or without NS-398 treatment. Data are mean ± SEM; * P < 0.05 or ** P < 0.01 versus the Sham group; # P < 0.05 versus the Vehicle group; unpaired two-tailed Student's t-test. n = 5 per group. (H) The mean CBS score in tSCI rats was improved by NS-398 treatment. Data are mean ± SEM; ** P < 0.05 versus the Sham group; # P < 0.05 versus the Vehicle group; unpaired two-tailed Student's t-test. n = 5 per group.